Financial support: The study was supported by the European Foundation for the Study of Chronic Liver Failure (EF-Clif). EF-Clif received unrestricted donations from Grifols and Cellex Foundations and is partner or contributor in several projects of the EU Horizon 2020 research program. Maria Papp was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Science (BO/00232/17/5) and the New National Excellence Program of the Ministry of Human Capacities (ÚNKP-18-4 Bolyai Plus). Pere Ginès is a recipient of the ICREA ACADEMIA AWARD (2015-2020). Disclosures The EASL-CLIF Consortium is a network of 101 European University hospitals supported by the EF-Clif. EF-Clif is a private non-profit organization aimed at improving clinical and translational research in cirrhosis. The scientific agenda of the EASL-CLIF Consortium and the specific research protocols are made exclusively by the Steering Committee members without any participation of pharmaceutical companies.

This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e17 (https://www. gastrojournal.org/cme/home). Learning Objective: Upon completion of this CME activity, successful learners will be able to (1) discuss the clinical relevance of normalizing serum albumin concentration in patients with decompensated cirrhosis and ascites and (2) identify the main mechanisms of action of albumin in this setting. Effects of long-term albumin treatment on serum albumin levels and inflammatory cytokines High albumin dose (HAlbD: 1.5 g/kg every week, blue figures) but not low albumin dose (LAlbD: 1 g/kg every 2 weeks: red figures) normalized serum albumin levels and decreased inflammatory cytokines

No abstract